ImmuCell Corporation
- ICCC
- NASDAQ
- Biotechnology
- Animal Health/Biologics
- Cattle Health Products
$10.51
Today −2.23%Quote Oct 19, 2026, 08:00 PM UTC
+5.63%over the last month
Max drawdown −5.2%From 1-month high −2.6%3 months −6.2%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
About ImmuCell
ImmuCell Corporation functions as an animal health enterprise, specializing in the creation, manufacturing, and commercialization of offerings aimed at improving the vitality and output of dairy and beef cattle, serving both the U.S. domestic market and international regions. Among its key products is First Defense, an orally administered preventative designed to combat scours in newborn dairy and beef calves.
Where the money comes from
Q4 2021 revenue $5.4M
- FirstDefenseProductLineMember$5.4M99.3%
- OtherAnimalHealthMember$40,5950.7%
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Employees
73
Market value
$95.5M
Quote Oct 19
Floor
$10.41
0.9% below price
Resistance
$10.82
3.0% above price
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about ICCCPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days free